» Articles » PMID: 26205061

Molecular Docking and Structure-based Drug Design Strategies

Overview
Journal Molecules
Publisher MDPI
Specialty Biology
Date 2015 Jul 25
PMID 26205061
Citations 556
Authors
Affiliations
Soon will be listed here.
Abstract

Pharmaceutical research has successfully incorporated a wealth of molecular modeling methods, within a variety of drug discovery programs, to study complex biological and chemical systems. The integration of computational and experimental strategies has been of great value in the identification and development of novel promising compounds. Broadly used in modern drug design, molecular docking methods explore the ligand conformations adopted within the binding sites of macromolecular targets. This approach also estimates the ligand-receptor binding free energy by evaluating critical phenomena involved in the intermolecular recognition process. Today, as a variety of docking algorithms are available, an understanding of the advantages and limitations of each method is of fundamental importance in the development of effective strategies and the generation of relevant results. The purpose of this review is to examine current molecular docking strategies used in drug discovery and medicinal chemistry, exploring the advances in the field and the role played by the integration of structure- and ligand-based methods.

Citing Articles

Exploiting the Achilles' heel of cancer through a structure-based drug-repurposing approach and experimental validation of top drugs using the TRAP assay.

Kaur D, Chopra M, Saluja D Mol Divers. 2025; .

PMID: 40087255 DOI: 10.1007/s11030-025-11162-1.


Diterpenes: Nature's Hidden Gems of Immunomodulation.

Almeida J, de Oliveira A, de Castro Alves C, Filho S, de Oliveira E, Zuliani J Int J Mol Sci. 2025; 26(5).

PMID: 40076871 PMC: 11900544. DOI: 10.3390/ijms26052250.


Comparison of PDE-5 inhibitors used in erectile dysfunction with some candidate molecules: A study involving molecular docking, ADMET, DFT, biological target, and activity.

Sagir S, Unsal V, Oner E, Yildiz R, Mert B BMC Urol. 2025; 25(1):47.

PMID: 40069715 PMC: 11895370. DOI: 10.1186/s12894-025-01727-5.


(Z)-N-(3-([1,1'-biphenyl]-2-yl)-4-heptyl-4-hydroxythiazolidin-2-ylidene)-4-bromobenzamide as carbonic anhydrase inhibitor: exploration of its in vitro and in silico studies.

Ahmed A, Ilyas S, Ali Channar P, Ejaz S, Saeed A, Ghumro S BMC Chem. 2025; 19(1):65.

PMID: 40065376 PMC: 11892125. DOI: 10.1186/s13065-025-01423-3.


Curcumol attenuates hyperproliferation and inflammatory response in a psoriatic HaCaT keratinocyte model by inhibiting the PI3K-Akt pathway and ameliorates skin lesions and inflammatory status in psoriasis-like mice.

Niu M, Li X, Li M, Chen F, Cao H, Liu Q Inflammopharmacology. 2025; .

PMID: 40063187 DOI: 10.1007/s10787-025-01708-y.


References
1.
Talele T, Kulkarni V . Three-dimensional quantitative structure-activity relationship (QSAR) and receptor mapping of cytochrome P-450(14 alpha DM) inhibiting azole antifungal agents. J Chem Inf Comput Sci. 1999; 39(2):204-10. DOI: 10.1021/ci9800413. View

2.
Gehlhaar D, Verkhivker G, Rejto P, Sherman C, Fogel D, FOGEL L . Molecular recognition of the inhibitor AG-1343 by HIV-1 protease: conformationally flexible docking by evolutionary programming. Chem Biol. 1995; 2(5):317-24. DOI: 10.1016/1074-5521(95)90050-0. View

3.
Das S, Krein M, Breneman C . Binding affinity prediction with property-encoded shape distribution signatures. J Chem Inf Model. 2010; 50(2):298-308. PMC: 2846646. DOI: 10.1021/ci9004139. View

4.
Rognan D, Lauemoller S, Holm A, Buus S, Tschinke V . Predicting binding affinities of protein ligands from three-dimensional models: application to peptide binding to class I major histocompatibility proteins. J Med Chem. 1999; 42(22):4650-8. DOI: 10.1021/jm9910775. View

5.
Amadasi A, Spyrakis F, Cozzini P, Abraham D, Kellogg G, Mozzarelli A . Mapping the energetics of water-protein and water-ligand interactions with the "natural" HINT forcefield: predictive tools for characterizing the roles of water in biomolecules. J Mol Biol. 2006; 358(1):289-309. DOI: 10.1016/j.jmb.2006.01.053. View